May 12, 2025: 3 Questions à MaaT Pharma – Direct Dirigeants (subtitled in English)

[divider line_type=”No Line”]

May 12, 2025: MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

May 13, 2025: Microbiome-Targeting Therapy MaaT033 Continues to Show Promise in Final Phase 1 Readout – Neurology Live